Anna Nijdam - 18 Mar 2026 Form 3 Insider Report for Pharvaris N.V. (PHVS)

Role: Principal Accounting Officer
Signature: /s/ Marnus Nel, Attorney-in-Fact for Anna Nijdam
Issuer symbol: PHVS
Transactions as of: 18 Mar 2026
Net transactions value: $0
Form type: 3
Filing time: 18 Mar 2026, 14:23:26 UTC
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Nijdam Anna	Principal Accounting Officer	1 CRANBERRY HILL SUITE 400, LEXINGTON	/s/ Marnus Nel, Attorney-in-Fact for Anna Nijdam	18 Mar 2026	0001973872

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	PHVS	Common Stock						51,819	18 Mar 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	PHVS	Stock Option (Right to Buy)							18 Mar 2026	Common Stock	30,000	$20.00	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -6,200 RSUs from an award granted March 3, 2026 of which 25% will vest on March 3, 2027 with the remainder vesting 25% on each annual anniversary; -6,150 RSUs from an award granted March 12, 2025 of which 25% vested March 12, 2026 with the remainder vesting 25% on each annual anniversary; -5,250 RSUs from an award granted April 11, 2024 of which 25% vested April 11, 2025 with the remainder vesting 25% on each annual anniversary; -7,500 RSUs from an award granted April 6, 2023 of which 25% vested April 6, 2024 with the remainder vesting 25% on each annual anniversary; -3,554 RSUs from an award granted April 1, 2022 of which 25% vested April 1, 2023 with the remainder vesting 25% on each annual anniversary.
F2	25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

Content

Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -6,200 RSUs from an award granted March 3, 2026 of which 25% will vest on March 3, 2027 with the remainder vesting 25% on each annual anniversary; -6,150 RSUs from an award granted March 12, 2025 of which 25% vested March 12, 2026 with the remainder vesting 25% on each annual anniversary; -5,250 RSUs from an award granted April 11, 2024 of which 25% vested April 11, 2025 with the remainder vesting 25% on each annual anniversary; -7,500 RSUs from an award granted April 6, 2023 of which 25% vested April 6, 2024 with the remainder vesting 25% on each annual anniversary; -3,554 RSUs from an award granted April 1, 2022 of which 25% vested April 1, 2023 with the remainder vesting 25% on each annual anniversary.

25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.